Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.

Q2 Medicine Oncotarget Pub Date : 2017-03-28 DOI:10.18632/oncotarget.15786
Lianghong Teng, Wanglong Deng, Junliang Lu, Jing Zhang, Xinyu Ren, Huanli Duan, Shannon Chuai, Feidie Duan, Wei Gao, Tao Lu, Huanwen Wu, Zhiyong Liang
{"title":"Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.","authors":"Lianghong Teng,&nbsp;Wanglong Deng,&nbsp;Junliang Lu,&nbsp;Jing Zhang,&nbsp;Xinyu Ren,&nbsp;Huanli Duan,&nbsp;Shannon Chuai,&nbsp;Feidie Duan,&nbsp;Wei Gao,&nbsp;Tao Lu,&nbsp;Huanwen Wu,&nbsp;Zhiyong Liang","doi":"10.18632/oncotarget.15786","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As a rare but aggressive papillary thyroid carcinoma (PTC) variant, the genetic changes of hobnail variant of PTC (HVPTC) are still unclear.</p><p><strong>Results: </strong>The prevalence of HVPTC was 1.69% (18/1062) of all PTC diagnosed in our cohort. 73 samples from 55 patients (17 HVPTC, 26 CPTC, 7 PDTC and 5 ATC) were successfully analyzed using targeted NGS with an 18-gene panel. Thirty-seven mutation variant types were identified among 11 genes. BRAF V600E mutation was the most common mutation, which is present in almost all HVPTC samples (16/17, 94%), most CPTC samples (20/26, 77%), and none of the ATC and PDTC samples. TERT promoter mutation (C228T) was identified in 2 ATC and one HVPTC patient. RAS and TP53 mutation are almost exclusively present among ATC and PDTC samples although TP53 mutation was also observed in 3 HVPTC patients. Six different GNAS mutations were identified among 8 CPTC patients (31%) and none of the HVPTC patients. The only patient who died of disease progression harbored concomitant TERT C228T mutation, BRAF V600E mutation and TP53 mutation.</p><p><strong>Methods: </strong>HVPTC cases were identified from a group of 1062 consecutive surgical specimens diagnosed as PTC between 2000 and 2010. Targeted next-generation sequencing (NGS) was applied to investigate the mutation spectrum of HVPTC, compared to classical PTC (CPTC), poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC).</p><p><strong>Conclusion: </strong>As an aggressive variant of PTC, HVPTC has relatively specific molecular features, which is somewhat different from both CPTC and ATC/PDTC and may underlie its relatively aggressive behavior.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"8 13","pages":"22023-22033"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.18632/oncotarget.15786","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.15786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 35

Abstract

Background: As a rare but aggressive papillary thyroid carcinoma (PTC) variant, the genetic changes of hobnail variant of PTC (HVPTC) are still unclear.

Results: The prevalence of HVPTC was 1.69% (18/1062) of all PTC diagnosed in our cohort. 73 samples from 55 patients (17 HVPTC, 26 CPTC, 7 PDTC and 5 ATC) were successfully analyzed using targeted NGS with an 18-gene panel. Thirty-seven mutation variant types were identified among 11 genes. BRAF V600E mutation was the most common mutation, which is present in almost all HVPTC samples (16/17, 94%), most CPTC samples (20/26, 77%), and none of the ATC and PDTC samples. TERT promoter mutation (C228T) was identified in 2 ATC and one HVPTC patient. RAS and TP53 mutation are almost exclusively present among ATC and PDTC samples although TP53 mutation was also observed in 3 HVPTC patients. Six different GNAS mutations were identified among 8 CPTC patients (31%) and none of the HVPTC patients. The only patient who died of disease progression harbored concomitant TERT C228T mutation, BRAF V600E mutation and TP53 mutation.

Methods: HVPTC cases were identified from a group of 1062 consecutive surgical specimens diagnosed as PTC between 2000 and 2010. Targeted next-generation sequencing (NGS) was applied to investigate the mutation spectrum of HVPTC, compared to classical PTC (CPTC), poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC).

Conclusion: As an aggressive variant of PTC, HVPTC has relatively specific molecular features, which is somewhat different from both CPTC and ATC/PDTC and may underlie its relatively aggressive behavior.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
兔甲变异型甲状腺乳头状癌的分子特征及与典型甲状腺乳头状癌、低分化甲状腺癌和间变性甲状腺癌的比较。
背景:甲钉型甲状腺乳头状癌(PTC)是一种罕见的侵袭性甲状腺乳头状癌(PTC)变体,其基因变化尚不清楚。结果:在我们的队列中,HVPTC的患病率为1.69%(18/1062)。采用靶向NGS技术成功分析了55例患者(17例HVPTC, 26例CPTC, 7例PDTC和5例ATC)的73份样本(18个基因面板)。在11个基因中鉴定出37种突变变异类型。BRAF V600E突变是最常见的突变,几乎在所有HVPTC样本(16/ 17,94%)中存在,大多数CPTC样本(20/ 26,77%)中存在,而ATC和PDTC样本中没有突变。在2例ATC和1例HVPTC患者中发现TERT启动子突变(C228T)。RAS和TP53突变几乎只存在于ATC和PDTC样本中,尽管在3例HVPTC患者中也观察到TP53突变。在8例CPTC患者(31%)和HVPTC患者中鉴定出6种不同的GNAS突变。唯一因疾病进展而死亡的患者同时存在TERT C228T突变、BRAF V600E突变和TP53突变。方法:从2000年至2010年间诊断为PTC的1062例连续手术标本中鉴定HVPTC病例。应用靶向新一代测序(NGS)技术研究HVPTC的突变谱,并与经典PTC (CPTC)、低分化甲状腺癌(PDTC)和间变性甲状腺癌(ATC)进行比较。结论:HVPTC作为PTC的侵袭性变体,具有相对特定的分子特征,与CPTC和ATC/PDTC有一定区别,可能是其具有相对侵袭性行为的原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncotarget
Oncotarget Oncogenes-CELL BIOLOGY
CiteScore
6.60
自引率
0.00%
发文量
129
审稿时长
1.5 months
期刊介绍: Information not localized
期刊最新文献
Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53. COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms. Nerofe+ldDox releases c-Jun from nuclear ST2 to reprogram the immune microenvironment in mtKRAS tumors. Machine learning-based survival prediction in colorectal cancer combining clinical and biological features. Correction: Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1